Clene Inc. has taken a significant step in the fight against amyotrophic lateral sclerosis (ALS) by submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational therapy, CNM-Au8. This submission, announced on October 19, 2026, is viewed as a crucial milestone for the company and its efforts to provide new treatment options for patients suffering from this debilitating condition.
Rob Etherington, President and Chief Executive Officer of Clene, expressed the importance of this achievement, stating, "The submission of our NDA for CNM-Au8 represents an important achievement for Clene, CNM-Au8, and especially for people living with ALS." He noted the constructive engagement from the FDA during the process and emphasized the urgency of providing additional treatment options for ALS patients.
Background
Clene Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. Clene is listed on the Nasdaq under the ticker symbol CLNN and is recognized as a smaller reporting company. The company is headquartered in Salt Lake City, Utah, and has been actively involved in advancing its research and development efforts in the field of neurodegenerative diseases.
What the Filing Says
The filing indicates that the NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes. Etherington highlighted the collaborative efforts of the Clene team, clinical investigators, and patients in reaching this stage, stating, "We remain focused on advancing CNM-Au8 through the regulatory process as efficiently as possible while continuing our preparations for the confirmatory Phase 3 RESTORE-ALS study." This reflects Clene's commitment to addressing the urgent needs of ALS patients.
Impact
This NDA submission is poised to affect various stakeholders, including patients, healthcare providers, and investors. For patients living with ALS, the potential approval of CNM-Au8 could offer a new avenue for treatment, addressing a significant unmet medical need. Healthcare providers may gain a new therapeutic option to consider in their treatment plans for ALS patients. Investors and analysts will be closely monitoring the FDA's response to this application, as it could influence Clene's market position and future growth prospects.
What's Next
The filing does not specify what happens next in the regulatory process. However, the company will likely continue to engage with the FDA as it reviews the NDA and prepares for the confirmatory Phase 3 RESTORE-ALS study.